Prostate cancer is a major health problem for U.S. men and is characterized by paradoxes and controversies. Despite the wide availability of the prostate-specific antigen (PSA) test, prostate cancer screening remains a controversial practice mainly because the direct impact of screening on mortality is not yet proven. As the relative value of screening, early detection, and treatment strategies continue to be debated, glaring racial-ethnic disparities persist with African American men experiencing excess morbidity and mortality and demonstrating the lowest screening rates among racial-ethnic groups. Given the prevailing controversy, uncertainty, and known disparities, how can health education messages be framed to assist men and their family members? This article highlights the ethnic disparities, paradoxes, and controversies of prostate cancer and identifies critical challenges and opportunities for health educators and clinical practitioners. Implications for health promotion communications and informed decision making in this era of uncertainty are discussed.
Abbott, R. R., Taylor, D. K., & Barber, K. (1998). A comparison of prostate knowledge of African-American and Caucasian men: Changes from prescreening baseline to postintervention. Cancer Journal from Scientific American, 4(3), 175-177.
2.
The Advisory Board Company. (2000). Oncology roundtable. Washington, DC: Author.
3.
American Cancer Society (ACS). (2004). Cancer statistics-2003. Atlanta, GA: Author.
4.
American College of Physicians. (1997). Screening for prostate cancer. Annals of Internal Medicine, 126, 480-484.
5.
Aus, G., Pileblad, E., & Hugosson, J. (2002). Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. European Urology, 42(2), 133-138.
6.
Auvinen, A., Alexander, F. E., de Koning, H. J., & Miller, A. B. (2002). Should we start population screening for prostate cancer? Randomised trials are still needed. International Journal of Cancer, 97(3), 377-378.
7.
Bahn, D. K., Lee, F., Badalament, R., Kumar, A., Greski, J., & Chernick, M. (2002). Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology, 60(2), S3-S11.
8.
Barber, K. R., Shaw, R., Folts, M., Taylor, D. K., Ryan, A., Hughes, M., et al. (1998). Differences between African American and Caucasian men participation in a community-based prostate cancer screening program. Journal of Community Health, 23(6), 441-451.
9.
Blasko, J. C., Mate, T., Sylvester, J. E., Grimm, P. D., & Cavanagh, W. (2002). Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Seminars in Radiation Oncology, 12(1), 81-94.
10.
Brawley, O. W., & Barnes, S. (2001). The epidemiology of prostate cancer in the United States. Seminars in Oncology Nursing, 17(2), 72-77.
11.
Burack, R. C., & Wood, D. P., Jr. (1999). Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness. Medical Clinics of North America, 83(6), 1423-1442.
12.
Byrd, W. M., & Clayton, L. A. (1993). The African-American cancer crisis, Part II: A prescription. Journal of Health Care for the Poor and Underserved, 4(2), 102-116.
13.
Cantor, S. B., Volk, R. J., Cass, A. R., Gilani, J., & Spann, S. J. (2002). Psychological benefits of prostate cancer screening: The role of reassurance. Health Expectations, 5(2), 104-113.
14.
Carter, H. B., & Pearson, J. D. (1997). Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urology Clinics of North America, 24(2), 333-338.
15.
Centers for Disease Prevention and Control (CDC). (2002, November 13). Prostate cancer screening: A decision guide. Retrieved September 12, 2003, from www.cdc.gov/cancer/prostate/decisionguide/index.htm
16.
Chan, E. C., Vernon, S. W., Haynes, M. C., O’Donnell, F. T., & Ahn, C. (2003). Physician perspectives on the importance of facts men ought to know about prostate-specific antigen testing. Journal of General Internal Medicine, 18(5), 350-356.
17.
Chan, E. C., Vernon, S. W., O’Donnell, F. T., Ahn, C., Greisinger, A., & Aga, D. W. (2003). Informed consent for cancer screening with prostate-specific antigen: How well are men getting the message?American Journal of Public Health, 93(5), 779-785.
18.
Chodak, G. W. (1994). The role of watchful waiting in the management of localized prostate cancer. Journal of Urology, 152(5 Pt 2), 1766-1768.
19.
Clayton, L. A., & Byrd, W. M. (1993). The African-American cancer crisis, Part I: The problem. Journal of Health Care for the Poor and Underserved, 4(2), 83-101.
20.
Clayton, L. A., Byrd, W. M., Kinchen, K., Richardson, D., Lawrence, L., Butcher, R., et al. (2001). Race: A major health status and outcome variable 1980-1999. Journal of the National Medical Association, 93(3), S35-S54.
21.
Cookson, M. M. (2001). Prostate cancer: Screening and early detection. Cancer Control, 8(2), 133-140.
22.
Demark-Wahnefried, W., Catoe, K. E., Paskett, E., Robertson, C. N., & Rimer, B. K. (1993). Characteristics of men reporting for prostate cancer screening. Urology, 42(3), 269-274.
23.
Demark-Wahnefried, W., McClelland, J., Campbell, M. K., Hoben, K., Lashley, J., Graves, C., et al. (1998). Awareness of cancer-related programs and services among rural African Americans. Journal of the National Medical Association, 90(4), 197-202.
24.
Demark-Wahnefried, W., Strigo, T., Catoe, K., Conaway, M., Brunetti, M., Rimer, B. K., et al. (1995). Knowledge, beliefs, and prior screening behavior among Blacks and Whites reporting for prostate cancer screening. Urology, 46(3), 346-351.
25.
Diefenbach, P. N., Ganz, P. A., Pawlow, A. J., & Guthrie, D. (1996). Screening by the prostate-specific antigen test: What do the patients know?Journal of Cancer Education, 11(1), 39-44.
26.
Donnelly, B. J., Saliken, J. C., Ernst, D. S., Ali-Ridha, N., Brasher, P. M., Robinson, J. W., et al. (2002). Prospective trial of cryosurgical ablation of the prostate: Five-year results. Urology, 60(4), 645-649.
27.
Durham, J., Low, M., & McLeod, D. (2003). Screening for prostate cancer: A survey of New Zealand general practitioners. New Zealand Medical Journal, 116(1176), U476-U476.
28.
Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H., et al. (2002). Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. Journal of National Cancer Institute, 94(13), 981-990.
29.
Fowler, F. J., Jr., Bin, L., Collins, M. M., Roberts, R. G., Oesterling, J. E., Wasson, J. H., et al. (1998). Prostate cancer screening and beliefs about treatment efficacy: A national survey of primary care physicians and urologists. American Journal of Medicine, 104(6), 526-532.
30.
Fowler, J. E., Jr., & Christie, D. W. (1997). African-American participation in prostate cancer screening. Urology, 50(3), 483-483.
31.
Franks, L. M. (1997). Prostatic cancer: Future prospects for diagnosis and screening. British Journal of Urology, 79(1), S107-S108.
32.
Frosch, D. L., Kaplan, R. M., & Felitti, V. (2001). The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. Journal of General Internal Medicine, 16(6), 391-398.
33.
Fulmer, B. R., Bissonette, E. A., Petroni, G. R., & Theodorescu, D. (2001). Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: Comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer, 91(11), 2046-2055.
34.
Gattellari, M., Young, J. M., & Ward, J. E. (2003). GP and patient predictors of PSA screening in Australian general practice. Family Practice, 20(3), 294-303.
35.
Germino, B. B. (2001). Psychosocial and educational intervention trials in prostate cancer. Seminars in Oncology Nursing, 17(2), 129-137.
36.
Gohagan, J. K., Prorok, P. C., Kramer, B. S., & Cornett, J. E. (1994). Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. Journal of Urology, 152(5 Pt 2), 1905-1909.
37.
Grimm, P. D., Blasko, J. C., Sylvester, J. E., Meier, R. M., & Cavanagh, W. (2001). 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. International Journal of Radiation Oncology, Biology, Physics, 51(1), 31-40.
38.
Gwede, C. K. (2001). Predictors of prostate cancer screening among African American men: A test of the preventive health model. Unpublished manuscript, Tampa, FL.
39.
Gwede, C. K., Forthofer, M. S., & McDermott, R. J. (2002). Awareness of prostate cancer screening tests among African American men in underserved neighborhoods: Need for community outreach. Journal of Oncology Management, 11(5), 36-41.
40.
Haas, G. P., & Sakr, W. A. (1997). Epidemiology of prostate cancer. CA: A Cancer Journal for Clinicians, 47(5), 273-287.
41.
Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Haggman, M., et al. (2002). A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine, 347(11), 781-789.
42.
Jemal, A., Tiwari, R. C.Murray, T., Ghafoor, A., Samuels, A., Ward, E., et al. (2004). Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8-29.
43.
Kuska, B. (1997). Kiwi conundrum: Screening for prostate cancer. Journal of the National Cancer Institute, 89(14), 1000-1000.
44.
Lipp, E. R. (2002). Web resources for patients with prostate cancer: A starting point. Seminars in Urologic Oncology, 20(1), 32-38.
45.
Litwin, M. S. (2000). A prospective, longitudinal study of the short-term effects of brachytherapy vs radical prostatectomy on health-related quality of life. Prostate Cancer and Prostatic Disease, 3(1), S26-S26.
46.
Litwin, M. S., Pasta, D. J., Yu, J., Stoddard, M. L., & Flanders, S. C. (2000). Urinary function and bother after radical prostatectomy or radiation for prostate cancer: A longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 164(6), 1973-1977.
47.
Livingston, P., Cohen, P., Frydenberg, M., Borland, R., Reading, D., Clarke, V., et al. (2002). Knowledge, attitudes and experience associated with testing for prostate cancer: A comparison between male doctors and men in the community. Intern Medicine Journal, 32(5-6), 215-223.
48.
Marks, S. (1997). Prostate and cancer: A family guide to diagnosis, treatment and survival. Tucson, AZ: Fisher Books.
49.
McCoy, C. B., Anwyl, R. S., Metsch, L. R., Inciardi, J. A., Smith, S. A., & Correa, R. (1995). Prostate cancer in Florida: Knowledge, attitudes, practices, and beliefs. Cancer Practice, 3(2), 88-93.
50.
Mettlin, C. J. (1998). Cancer epidemiology 50 years later. Cancer, 83(7), 1275-1277.
51.
Mettlin, C. J., & Murphy, G. P. (1998). Why is the prostate cancer death rate declining in the United States?Cancer, 82(2), 249-251.
52.
Mettlin, C. J., Murphy, G. P., Babaian, R. J., Chesley, A., Kane, R. A., Littrup, P. J., et al. (1997). Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer, 80(9), 1814-1817.
53.
Myers, R. E. (1999). African American men, prostate cancer early detection examination use, and informed decision-making. Seminars in Oncology, 26(4), 375-381.
54.
Myers, R. E., Chodak, G. W., Wolf, T. A., Burgh, D. Y., McGrory, G. T., Marcus, S. M., et al. (1999). Adherence by African American men to prostate cancer education and early detection. Cancer, 86(1), 88-104.
55.
National Cancer Institute (NCI). (2003, June 19). Screening for prostate cancer. Retrieved September 19, 2003, from www.cancer.gov/cancerinfo/pdq/screening/prostate/HealthProfessional
56.
O’Dell, K. J., Volk, R. J., Cass, A. R., & Spann, S. J. (1999). Screening for prostate cancer with the prostate-specific antigen test: Are patients making informed decisions?Journal of Family Practice, 48(9), 682-688.
57.
Ragde, H., Grado, G. L., Nadir, B., & Elgamal, A. A. (2000). Modern prostate brachytherapy. CA: A Cancer Journal for Clinicians, 50(6), 380-393.
58.
Ragde, H., Korb, L. J., Elgamal, A. A., Grado, G. L., & Nadir, B. S. (2000). Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer, 89(1), 135-141.
59.
Scher, H. I., Isaacs, J. T., & Zelefsky, M. J. (2000). Prostate cancer. In M. D. Abeloff, J. O. Armittage, A. S. Lichter, & J. E. Niederhuber (Eds.), Clinical oncology (2nd ed., pp. 1823-1884). New York: Churchill Livingstone.
60.
Smith, J. A., Jr. (2002). Informed choice in cancer screening. Journal of Urology, 167(1), 422-422.
61.
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2004). American Cancer Society guidelines for the early detection of cancer, 2004. CA: A Cancer Journal for Clinicians, 54(1), 41-52.
62.
Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D., et al. (2002). American Cancer Society guidelines for the early detection of cancer. CA: A Cancer Journal for Clinicians, 52(1), 8-22.
63.
Smith, R. A., von Eschenbach, A. C., Wender, R., Levin, B., Byers, T., Rothenberger, D., et al. (2001). American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early lung cancer detection. CA: A Cancer Journal for Clinicians, 51(1), 38-750.
64.
Standaert, B., & Denis, L. (1997). The European Randomized Study of Screening for Prostate Cancer: An update. Cancer, 80(9), 1830-1834.
65.
Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P. W., Johansson, J. E., Norlen, B. J., et al. (2002). Quality of life after radical prostatectomy or watchful waiting. New England Journal of Medicine, 347(11), 790-796.
66.
Talcott, J. A., Clark, J. A., Stark, P. C., & Mitchell, S. P. (2001). Longterm treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated. Journal of Urology, 166(2), 494-499.
67.
Tingen, M. S., Weinrich, S. P., Heydt, D. D., Boyd, M. D., & Weinrich, M. C. (1998). Perceived benefits: a predictor of participation in prostate cancer screening. Cancer Nursing, 21(5), 349-357.
68.
Tudiver, F., Brown, J. B., Medved, W., Herbert, C., Ritvo, P., Guibert, R., et al. (2001). Making decisions about cancer screening when the guidelines are unclear or conflicting. Journal of Family Practice, 50(8), 682-687.
69.
Tudiver, F., Guibert, R., Haggerty, J., Ciampi, A., Medved, W., Brown, J. B., et al. (2002). What influences family physicians’ cancer screening decisions when practice guidelines are unclear or conflicting?Journal of Family Practice, 51(9), 760-760.
70.
U.S. Preventive Services Task Force. (2002). Screening for prostate cancer: Recommendation and rationale. Annals of Internal Medicine, 137, 915-916.
71.
Voss, J. D., & Schectman, J. M. (2001). Prostate cancer screening practices and beliefs. Journal of General Internal Medicine, 16(12), 831-837.
72.
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., et al. (2002). Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. Journal of Clinical Oncology, 20(2), 557-566.
73.
Weinrich, S. (2001). The debate about prostate cancer screening: what nurses need to know. Seminars in Oncology Nursing, 17(2), 78-84.
74.
Weinrich, S., Holdford, D., Boyd, M., Creanga, D., Cover, K., Johnson, A., et al. (1998). Prostate cancer education in African American churches. Public Health Nursing, 15(3), 188-195.
75.
Weinrich, S. P., Boyd, M. D., Weinrich, M., Greene, F., Reynolds, W. A., Jr., & Metlin, C. (1998). Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. Journal of Cancer Education, 13(4), 213-219.
76.
Weinrich, S. P., Greiner, E., Reis-Starr, C., Yoon, S., & Weinrich, M. (1998). Predictors of participation in prostate cancer screening at worksites. Journal of Community Health Nursing, 15(2), 113-129.
77.
Weinrich, S. P., Reynolds, W. A., Jr., Tingen, M. S., & Starr, C. R. (2000). Barriers to prostate cancer screening. Cancer Nursing, 23(2), 117-121.
78.
Weinrich, S. P., Weinrich, M. C., Boyd, M. D., & Atkinson, C. (1998). The impact of prostate cancer knowledge on cancer screening. Oncology Nursing Forum, 25(3), 527-534.
79.
Weinrich, S. P., Weinrich, M. C., Priest, J., & Fodi, C. (2003). Selfreported reasons men decide not to participate in free prostate cancer screening. Oncology Nursing Forum, 30(1), E12-E16.
80.
Wilt, T. J. (1998a). Can randomized treatment trials in early stage prostate cancer be completed?Clinical Oncology (Royal College of Radiology), 10(3), 141-143.
81.
Wilt, T. J. (1998b). Prostate cancer screening: Practice what the evidence preaches. American Journal of Medicine, 104(6), 602-604.
82.
Wilt, T. J., & Brawer, M. K. (1997). The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntington), 11(8), 1133-1139.
83.
Wilt, T. J., Paul, J., Murdoch, M., Nelson, D., Nugent, S., & Rubins, H. B. (2001). Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet. Effective Clinical Practice, 4(3), 112-120.
84.
Yu, H. J., & Lai, M. K. (1998). The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer. Urology, 51(5A), S125-S130.
